Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Baudax Bio, Inc.BXRX · Entity 109081 | Director | April 07, 2021 | April 08, 2021 |
| INSMED IncINSM · Entity 3174 | Director | May 13, 2024 | May 15, 2024 |
| Societal CDMO, Inc.REPH · Entity 92137 | Director | December 05, 2019 | December 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Baudax Bio, Inc.
Report date April 07, 2021 · Filed April 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,785 |
Reported balance
After 2021-04-07 transaction · row 1
1 source rowRow 1 · 2021-04-07 · Grant · Acquired 56,452 · Balance 117,785 F1: All shares of common stock are represented by unvested restricted stock units that will vest on April 7, 2022. Vested shares will be delivered to the reporting person within 30 days following the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2031-04-07 | Direct | 83,333 |
Reported balance
After 2021-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-07 · Grant · Acquired 83,333 · Balance 83,333 F2: The stock option will vest on April 7, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of common stock are represented by unvested restricted stock units that will vest on April 7, 2022. Vested shares will be delivered to the reporting person within 30 days following the vesting date.
F2: The stock option will vest on April 7, 2022.
INSMED Inc
Report date May 13, 2024 · Filed May 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,495 |
Reported balance
After 2024-05-13 transaction · row 1
1 source rowRow 1 · 2024-05-13 · Grant · Acquired 13,162 · Balance 69,495 F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2: Each RSU was granted on May 13, 2024 for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date.
F2: Each RSU was granted on May 13, 2024 for no consideration.
Societal CDMO, Inc.
Report date December 05, 2019 · Filed December 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,196 |
Reported balance
After 2019-12-05 transaction · row 1
1 source rowRow 1 · 2019-12-05 · Grant · Acquired 15,284 · Balance 44,196 F1: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AGILE THERAPEUTICS INC
Report date August 26, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-26 · Disposition to issuer · Disposed 28,125 · Balance 19,624 F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 28,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $42,750, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person. Row 2 · 2024-08-26 · Disposition to issuer · Disposed 19,624 · Balance 0 F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 19,624 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $29,828, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 28,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $42,750, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 19,624 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $29,828, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2019 Filed Jan 14, 2019 21:15 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,500 | $22.50 | $123,750.00 |
DisclosureSEC source: 0001127430-19-000025 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,442 F1 · price: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-18-041577 · a4.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: This option was granted on June 20, 2018. 25% of the shares subject to the stock option vested on the date of grant. The remaining shares vest in 3 equal 25% installments on December 31, 2018, June 30, 2019 and December 31, 2019. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:13 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-18-000037 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,942 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 12, 2018 Filed May 14, 2018 16:50 UTC | Societal CDMO, Inc. REPH · Entity 92137 | Exercise / conversionRestricted Stock Units · Derivative | 13,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000204 · edgar.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 12, 2017, the reporting person was granted 13,274 restricted stock units, vesting on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 12, 2017, the reporting person was granted 13,274 restricted stock units, vesting on the first anniversary of the grant date. Read SEC document |
| May 12, 2018 Filed May 14, 2018 16:50 UTC | Societal CDMO, Inc. REPH · Entity 92137 | Exercise / conversionCommon Stock | 13,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-18-000204 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 04, 2018 Filed May 8, 2018 17:27 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 5,742 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000184 · edgar.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,742 Underlying: Common Stock · 5,742 shares Expires 2028-05-04 F2 · derivative.exercise_date: The stock option will vest on May 4, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 17:27 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 6,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000184 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,683 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 4, 2019. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| May 04, 2018 Filed May 10, 2018 18:58 UTC Amendment | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 8,965 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000196 · edgar.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,965 Underlying: Common Stock · 8,965 shares Expires 2028-05-04 F1 · shares: This amended Form 4 is being filed to correct a typographical error in the number of stock options acquired on May 4, 2018 as reported on the Form 4 filed on May 8, 2018. F2 · derivative.exercise_date: The stock option will vest on May 4, 2019. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 16:31 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-008061 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,314 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: 50,000 restricted stock units were granted on February 8, 2016 and vest as follows: 16,666 units vested and were delivered on the grant date, 16,667 units vested and were delivered on February 8, 2017, and 16,667 units vested and were delivered on February 8, 2018; The 35,314 remaining restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019. F2 · derivative.expiration_date: 50,000 restricted stock units were granted on February 8, 2016 and vest as follows: 16,666 units vested and were delivered on the grant date, 16,667 units vested and were delivered on February 8, 2017, and 16,667 units vested and were delivered on February 8, 2018; The 35,314 remaining restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 16:31 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 16,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-008061 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:14 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantRestricted Stock Units · Derivative | 35,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-004312 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,981 Underlying: Common Stock · 35,314 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019. F3 · derivative.expiration_date: The restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:14 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 256,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001104659-18-004312 · a4.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,000 Underlying: Common Stock · 256,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2018. 25% of the shares subject to the stock option vest on January 24, 2019, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 24, 2022 Read SEC document |
| August 25, 2017 Filed Aug 28, 2017 16:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 10,000 | $3.34 | $33,400.00 |
DisclosureSEC source: 0001104659-17-054004 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chairman & Chief Executive Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,587 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $3.32 to $3.34, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:28 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-17-000040 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,876 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was received as a grant on May 17, 2017, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 12, 2017 Filed May 16, 2017 16:28 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantRestricted Stock Units · Derivative | 13,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-17-000940 · edgar.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,274 Underlying: Common Stock · 13,274 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 12, 2018. Vested shares will be delivered to the reporting person within 30 days following the vesting date. F2 · derivative.expiration_date: The restricted stock units vest on May 12, 2018. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| May 11, 2017 Filed May 12, 2017 07:50 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 10,000 | $3.51 | $35,100.00 |
DisclosureSEC source: 0001104659-17-032097 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chairman and Chief Executive O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,587 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $3.34 to $3.59, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 11, 2017 Filed Apr 12, 2017 16:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001104659-17-023100 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chairman & Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,599 Underlying: Common Stock · 30,000 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on December 9, 2010 and is currently fully vested and exercisable. Read SEC document |
| April 11, 2017 Filed Apr 12, 2017 16:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 30,000 | $1.76 | $52,800.00 |
DisclosureSEC source: 0001104659-17-023100 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chairman & Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-008208 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: 50,000 restricted stock units were granted on February 8, 2016 and vest as follows: 16,666 units vested and were delivered on the grant date, 16,667 units vested and were delivered on February 8, 2017, and 16,667 units will vest and be delivered on February 8, 2018. F2 · derivative.expiration_date: 50,000 restricted stock units were granted on February 8, 2016 and vest as follows: 16,666 units vested and were delivered on the grant date, 16,667 units vested and were delivered on February 8, 2017, and 16,667 units will vest and be delivered on February 8, 2018. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 16,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-008208 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 16:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001104659-17-004561 · a4.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: This option was granted on January 25, 2017. 25% of the shares subject to the stock option vest on January 25, 2018, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 25, 2021. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 16:52 UTC | Societal CDMO, Inc. REPH · Entity 92137 | PurchaseCommon Stock | 1,500 | $6.55 | $9,825.00 |
DisclosureSEC source: 0001123292-16-003064 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.51 to $6.59, inclusive. The reporting person undertakes to provide to Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.